Pregabalin Pfizer

RSS

pregabalin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Pregabalin Pfizer. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Pfizer.

For practical information about using Pregabalin Pfizer, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 19/06/2019

Authorisation details

Product details
Name
Pregabalin Pfizer
Agency product number
EMEA/H/C/003880
Active substance
pregabalin
International non-proprietary name (INN) or common name
pregabalin
Therapeutic area (MeSH)
  • Anxiety Disorders
  • Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX16
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
10/04/2014
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

21/05/2019 Pregabalin Pfizer - EMEA/H/C/003880 - N/0030

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiepileptics

Therapeutic indication

Neuropathic pain

  • Pregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy

  • Pregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised Anxiety Disorder

  • Pregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Assessment history

How useful was this page?

Add your rating
Average
1 rating